Medikit (7749) Q2 2025 earnings summary

Executive summary

• Revenue for the six months ended September 30, 2024, increased by 4.1% year-over-year to ¥11,285 million, while operating income declined by 2.5% to ¥2,220 million and net income attributable to shareholders fell by 3.2% to ¥1,278 million.

• Domestic sales growth was driven by strong performance in dialysis and intravenous catheter products, while overseas sales were impacted by the end of a major distribution contract.

• The company revised its mid-term management plan to adapt to changing market conditions and continues to focus on product innovation and expansion in both domestic and international markets.

Financial highlights

• Gross profit for the period was ¥4,296 million, with a gross margin of 38.1%, down from 40.7% in the prior year.

• Operating cash flow decreased 42.3% year-over-year to ¥1,408 million, while investing cash outflows rose sharply due to increased capital expenditures.

• EPS for the interim period was ¥86.40, up from ¥78.64 in the previous year.

Outlook and guidance

• Full-year revenue is forecast at ¥22,385 million (up 2.4% year-over-year), with operating income expected to decline 11.0% to ¥4,162 million and net income to decrease 10.6% to ¥2,745 million.

• No changes have been made to the previously announced full-year guidance.